Filing Flows › iSpecimen (ISPC) › Q4 2024
iSpecimen (ISPC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 14, 2025
iSpecimen (ISPC) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), -43% from a year earlier and -45% from the quarter before. Operating margin was -395.8%, net loss $6.0M (409.8% of revenue).
iSpecimen, Q4 2024: revenue $1.5M (-43% year over year), operating margin -395.8%, net loss $6.0M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -45% | -43% |
| Operating profit | −$5.8M | — | — |
| Net earnings | −$6.0M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $1.5M in Q4 2024, down 43% year over year and down 45% from the previous quarter. Product was the largest line at 92% of revenue.
Operating costs exceeded revenue by $5.8M, an operating margin of -395.8%. Total costs grew 34% against a revenue fall of 43%. The fastest-growing cost line was Sales & marketing (+161%). The quarter ended with a net loss of $6.0M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$3.6M. Non-cash charges added back $548K of depreciation and amortization and $11K of share-based compensation. Working capital and other items added $1.9M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$3.6M.
Questions
What was iSpecimen's revenue in the fourth quarter 2024?
iSpecimen (ISPC) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), -43% from a year earlier and -45% from the quarter before.
Was iSpecimen profitable in the fourth quarter 2024?
Operating loss was $5.8M (-395.8% of revenue) and net loss $6.0M.
Source: iSpecimen 10-K on SEC EDGAR.